marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 10-30-2024
Processa Pharmaceuticals Income Statement 2011-2024 | PCSA
Annual Income Statement Processa Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
3.11 M | 371 K | 58.7 M | 35.2 M | 45.6 M | 119 M | 134 M | 1.66 M | 4.41 M | 19 M | - | - | - |
Shares |
1.31 M | 805 K | 15.3 M | 5.59 M | 5.53 M | 5.33 M | 4.66 M | 225 K | 225 K | 181 K | - | - | - |
Historical Prices |
2.37 | 0.46 | 3.83 | 11.4 | 9.75 | 18.2 | 21 | 7.4 | 19.6 | 106 | - | - | - |
Net Income |
-11.1 M | -27.4 M | -11.4 M | -14.4 M | -3.36 M | -3.77 M | -1.86 M | -336 K | -3.35 M | -4.53 M | -3.07 M | -2.44 M | -940 K |
Revenue |
- | - | - | - | - | - | - | 5 K | 113 K | 200 K | 312 K | 192 K | 20 K |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | 5 K | -12.5 K | 87 K | 124 K | 58.9 K | 20 K |
Operating Income |
-11.5 M | -27.5 M | -12.1 M | -15.1 M | -3.94 M | -4.52 M | -1.8 M | -1.92 M | - | - | - | - | - |
Interest Expense |
- | - | - | 281 K | 36.7 K | 161 K | 59.1 K | 245 K | 236 K | 315 K | -110 K | -171 K | - |
EBITDA |
-11.5 M | -26.7 M | -12.1 M | -5.63 M | -3.13 M | -3.89 M | -1.8 M | -71.4 K | -748 K | -2.49 M | -2.55 M | -2.16 M | -1.11 M |
Operating Expenses |
- | - | - | 6.44 M | 3.94 M | 4.52 M | 1.8 M | 76.5 K | 975 K | 3.03 M | 3.09 M | 2.33 M | 790 K |
General and Administrative Expenses |
5.66 M | 8.76 M | 4.69 M | 3.26 M | 1.61 M | 1.44 M | 876 K | 70 K | 945 K | - | - | - | 610 K |
All numbers in USD currency
Quarterly Income Statement Processa Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
3.28 M | 2.98 M | 1.29 M | 1.35 M | 1.35 M | 22.8 M | 16 M | 16.2 M | 15.9 M | 15.8 M | 15.7 M | 15.5 M | 15.4 M | 14.6 M | 14.2 M | 5.59 M | 5.52 M | 5.52 M | 5.49 M | 5.53 M | 5.53 M | 5.53 M | 5.53 M | 38.7 M | 36.6 M | 35.3 M | 35.1 M | 31.7 M | 31.7 M | 31.7 M | 31.7 M | 31.7 M | 26.9 M | 26.9 M | 11 M | 11 M | 11 M | 11 M | 11 M | 8.43 M | 8.4 M | 8.26 M | 8.08 M | 7.84 M | 2.23 M | 1.9 M | - | 1.75 M | 1.75 M | - | - | - | - | - |
Net Income |
-3.38 M | -3.01 M | - | -2.08 M | -2.61 M | -4.02 M | - | -6.02 M | -5.16 M | -3.23 M | - | -2.99 M | -3.16 M | -2.1 M | - | -3.07 M | -733 K | -874 K | - | -864 K | -969 K | -751 K | - | -853 K | -1.21 M | -1.1 M | -634 K | -712 K | -278 K | -232 K | -234 K | -827 K | -574 K | -281 K | - | -296 K | -2.05 M | -645 K | - | -792 K | -851 K | -1.34 M | - | -719 K | -727 K | -816 K | - | -602 K | -475 K | - | - | - | - | - |
Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5 K | 5 K | 5 K | - | 17.6 K | 32.8 K | 32.8 K | - | 16.6 K | 77 K | 7.44 K | - | 119 K | 96 K | 19.2 K | - | 48.6 K | 97 K | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5 K | 5 K | 5 K | - | 15.5 K | 9.03 K | 12.8 K | - | 27.3 K | 42.6 K | 11.2 K | - | 45.5 K | 35.8 K | 7.08 K | - | 15.1 K | 43.2 K | - | - | - | - | - |
Operating Income |
-3.42 M | -3.08 M | - | -2.17 M | -2.71 M | -4.11 M | - | -6.06 M | -5.17 M | -3.23 M | - | -3.11 M | -3.46 M | -2.19 M | - | -2.96 M | -802 K | -986 K | - | -1 M | -1.14 M | -883 K | - | -1.06 M | -1.43 M | -1.29 M | - | -713 K | -280 K | -234 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | 71.7 K | - | - | 102 K | 83.5 K | - | - | 7.38 K | 1.58 K | - | - | 362 | 362 | - | 186 K | 19.3 K | 17.2 K | - | 2.27 K | 6.1 K | 4.6 K | - | 8.32 K | 58.3 K | 87.7 K | 59.1 K | 44.2 K | 63.4 K | 61.9 K | - | 63.3 K | 62.6 K | 56.1 K | - | 55 K | 47.7 K | 35.3 K | - | 130 K | 113 K | -60.1 K | - | -45.4 K | -33.8 K | -15.9 K | - | -34.7 K | -69.9 K | - | - | - | - | - |
EBITDA |
- | - | - | - | - | - | - | -5.86 M | -4.78 M | -3.03 M | - | -3.11 M | -3.46 M | -2.19 M | - | -2.95 M | -798 K | -984 K | - | -998 K | -1.13 M | -880 K | - | -1.06 M | -1.42 M | -1.29 M | - | -716 K | -279 K | -234 K | - | 159 | 159 | 159 | - | 10.1 K | 23.9 K | 19.1 K | - | 22.4 K | 23.4 K | 21.8 K | - | 14.5 K | 13.2 K | 13 K | - | 4.68 K | 715 | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.96 M | 802 K | - | - | 1 M | 1.14 M | - | - | 1.06 M | 1.43 M | 1.29 M | 575 K | 713 K | 280 K | 234 K | 236 K | 4.97 K | 8.98 K | 80.5 K | - | 140 K | 1.89 M | 471 K | - | 689 K | 781 K | 1.3 M | - | 720 K | 729 K | 808 K | - | 583 K | 448 K | - | - | - | - | - |
General and Administrative Expenses |
1.14 M | 1.35 M | - | 1.02 M | 1.03 M | 2.48 M | - | 2.92 M | 2.03 M | 1.18 M | - | 1.34 M | 1.33 M | 717 K | - | 423 K | 375 K | 484 K | - | 419 K | 410 K | 398 K | - | 451 K | 351 K | 470 K | - | 255 K | 119 K | 94 K | - | 4.4 K | 3.28 K | 80.5 K | - | 84.2 K | 362 K | 459 K | - | 677 K | 712 K | 805 K | - | 664 K | 666 K | 737 K | - | 519 K | 300 K | - | - | - | - | - |
All numbers in USD currency